Articles tagged "Sensitization"

2021 American Transplant Congress
Successful Prophylaxis of Antibody-Mediated Rejection by Downregulation of C5 Expression via RNA Interference in a Rat Kidney Transplant Model
H. Ishigooka¹, S. Motoi², T. Yamakawa¹, C. Matsui², Y. Suzuki³, R. Ishii¹, K. Saiga¹, D. Tokita¹, T. Imai², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²KAN Research Institute, Inc., Kobe, Japan, ³Tsukuba Research Laboratories, Eisai, Co., Ltd., Ibaraki, Japan
*Purpose: Antibody-mediated rejection (AMR) is a major contributor towards poor prognosis in kidney transplantation. Circulating donor-specific antibodies (DSAs) cause AMR with complement activation. This study…
2020 American Transplant Congress
Costimulation Blockade-Based Maintenance Immunosuppression in a Sensitized Nonhuman Primate Kidney Allotransplantation Model
R. Schmitz, Z. W. Fitch, P. M. Schroder, A. Y. Choi, M. Manook, J. Yoon, J. Kwun, S. J. Knechtle
Department of Surgery, Duke University Medical Center, Durham, NC
*Purpose: Sensitized transplant recipients represent a challenging population in part due to the presence of donor-specific antibodies (DSA), which increase the risk of antibody-mediated rejection.…
2020 American Transplant Congress
Estimating Alloantibody Levels in Highly-Sensitized Renal Allograft Candidates Using Serial Dilutions
C. Maguire¹, A. R. Tambur¹, C. Schinstock², M. D. Stegall²
¹Northwestern University, Chicago, IL, ²Mayo Clinic, Rochester, MN
*Purpose: Despite the new Kidney Allocation System and Kidney Paired Donation, renal allograft candidates with a >99.9% cPRA still have extremely low rates of transplantation…
2020 American Transplant Congress
Effect of Maintaining Immunosuppression after Kidney Graft Failure on Mortality and Re-Transplantation
C. Schinstock, S. Balakrishnan, A. Bentall, M. Merzkani, M. Stegall
Mayo Clinic, Rochester, MN
*Purpose: Patients with a failed renal allograft are at high risk for mortality. The potential benefit of maintaining immunosuppression with the intent to minimize sensitization…
2020 American Transplant Congress
Bone Marrow Plasma Cell Heterogeneity Drives Resistance of Proteasome Inhibitor Therapy
C. M. Castro-Rojas¹, S. Tremblay², J. Driscoll³, K. Roskin⁴, R. R. Alloway³, E. Woodle², D. A. Hildeman¹
¹Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, ²Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, ³Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH
*Purpose: Patients sensitized to HLA antigens by prior transplantation, pregnancy or blood transfusion may have markedly prolonged waiting times for transplant. Moreover, once transplanted, the…
2020 American Transplant Congress
Desensitization for Deceased Donor Transplantation: Testing a New Paradigm in the Nonhuman Primate
Z. W. Fitch, R. Schmitz, P. M. Schroder, M. Manook, A. Y. Choi, J. Yoon, J. Kwun, S. J. Knechtle
Duke University, Durham, NC
*Purpose: Desensitization regimens have rarely been applied to deceased donor allotransplantation. We hypothesized that belatacept monotherapy during a simulated deceased donor waiting list period would…
2020 American Transplant Congress
Targeting the CD40/CD40L Axis in Sensitized Nonhuman Primate Allotransplantation
Z. W. Fitch, R. Schmitz, M. Manook, A. Y. Choi, J. Yoon, J. Kwun, S. J. Knechtle
Duke University, Durham, NC
*Purpose: Blockade of the CD28/B7 costimulation pathway has shown great promise as part of desensitization and maintenance immunosuppression regimens in our sensitized nonhuman primate model.…
2020 American Transplant Congress
Posttransplant Prophylactic Therapy with IVIG/Plasmapheresis in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies
T. V. Sandes-Freitas, B. Neri, J. Junqueira Junior, T. Leite, M. Sales, R. Esmeraldo
Hospital Geral de Fortaleza, Fortaleza, Brazil
*Purpose: Patients with high levels of preformed donor-specific antibodies (DSA) are often not considered for kidney transplantation (KT), despite negative CDC-crossmatch, mainly in regions where…
2020 American Transplant Congress
Dissecting Humoral Alloimmune Sensitization: A Dynamic Interplay of Different Cellular Compartments
A. Torija, A. Favà, E. Crespo, M. Jarque, M. Meneghini, N. Bolaños, J. Grinyo, O. Bestard
Kidney transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain
*Purpose: Humoral alloimmune memory is the main barrier for successful transplantation and is generated by a complex and compartmentalized B-cell immune response. Understanding the role…
2020 American Transplant Congress
Daratumumab for Desensitization and Antibody Mediated Rejection Treatment in Highly-HLA Sensitized Patients
S. Jordan, R. Vescio, N. Ammerman, M. Toyoda, S. Ge, M. Chu, J. Hou, E. Huang, A. Peng, S. Sethi, R. Najjar, K. Lim, J. Kobashigawa, J. Patel, E. Kransdorf, A. Vo
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly-HLA sensitized (HS) patients have an immunologic barrier to transplantation. ABMR promotes graft loss and poor patient survival. Methods to reduce anti-HLA antibodies are…